SCHEMBL23972866

SCHEMBL23972866

CC(C)c1csc(C2(c3nc4c(c(=O)[nH]3)CN(C(=O)OC(C)(C)C)CC4)CC2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 3/20 0.36
MAPT P10636 2/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
FABP4 P15090 1/20 0.36
FABP5 Q01469 1/20 0.36
GRAMD1A Q96CP6 1/20 0.36
F12 P00748 1/20 0.36
PARP1 P09874 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
MTHFD2 P13995 5/20 0.35
PDE10A Q9Y233 1/20 0.34
ESR2 Q92731 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23973122 0.95 SPR (0.39) SPRMAPTDDB1CRBNFABP4
SCHEMBL23973297 0.90 SPR (0.39) SPRMAPTDDB1CRBNFABP4
SCHEMBL23973271 0.90 MAPT (0.37) SPRMAPTDDB1CRBNFABP4
SCHEMBL23972445 0.88 MTHFD2 (0.43) SPRMAPTDDB1CRBNF12
SCHEMBL23972872 0.87 SPR (0.36) SPRMAPTDDB1CRBNFABP4
SCHEMBL23973284 0.87 F12 (0.36) SPRMAPTDDB1CRBNFABP4
SCHEMBL23973283 0.87 MAPT (0.37) SPRMAPTDDB1CRBNFABP4
SCHEMBL23972310 0.86 PDE10A (0.42) SPRMAPTDDB1CRBNF12
SCHEMBL23973109 0.85 SPR (0.36) SPRMAPTDDB1CRBNFABP4
SCHEMBL23973214 0.85 SPR (0.40) SPRMAPTDDB1CRBNFABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 SPR 840/4885MAPT 2065/4885DDB1 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.